StockNoteStockNote
Ben Tre Pharmaceutical Joint Stock Company (DBT), formerly known as Ben Tre Pharmaceutical Enterprise, was established in 1983 on the basis of merging two enterprises, Ben Tre Pharmaceutical Company and Ben Tre Pharmaceutical Enterprise. The company's main business is the manufacture and import of medicines. The company owns 3 GMP who factories with a total area of more than 11,000m2. Extensive distribution network with 6 branches: Hanoi, Da Nang, Ninh Binh, Khanh Hoa, Ho Chi Minh and Can Tho. Particularly in the province, the company distributes goods to 1,257 customers including 16 companies, 33 hospitals – medical centers, 126 medical stations, 111 pharmacies, 638 agents, 196 clinics. On October 28, 2020, DBT was officially traded at the Ho Chi Minh Stock Exchange (hose).
DBT currently has a market capitalization of roughly VND 289 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 10,3x is 16% below its own 8-year average (12,2x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 1x, 7% above its multi-year average of 0,9x. Return on equity (ROE) is at 9,4%, up from 4,9% the year before. Its debt-to-equity ratio of 1,6x is relatively high, reflecting a leveraged capital structure. In 2025, revenue fell 1% year-on-year while after-tax profit grew 18%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.